510(k) · Cleared
ClearedTissue of Origin Test Kit Ffpe
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Pathwork Diagnostics, Inc. · OIW Software, Similarity Score Algorithm, Tissue Of Origin For Malignant Tumor Types
Cleared on May 17, 2012 as substantially equivalent to K092967 (Pathwork Diagnostics, 2010) after a 90-day review. Its family tree reaches back 4 generations to 1995. 1 later device descends from it.
- Decided
- May 17, 2012
- Review
- 90 days
- Class
- Class II
- Product code
- OIW
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 4 generations to K941596 (1995). 1 later device descends from it, 1 citing it directly.
- Root · 4 generations backK941596 Remedi HS Drug Profiling SystemBio-Rad · 1995
- 3 generations backK043341 Bioplex 2200 Ana Screen with Medical Decision Support Software for…Bio-Rad Laboratories, Inc. · 2005 · Recalled
- 2 generations backK080896 Pathwork Diagnostics Tissue of Origin TestPathwork Diagnostics, Inc. · 2008
- 1 generation backK092967 Pathwork Tissue of Origin Test Kit-Ffpe (Origin Test Kit-FfpePathwork Diagnostics · 2010
- This deviceK120489 Tissue of Origin Test Kit FfpePathwork Diagnostics, Inc. · 2012
- Descendant · cites it directly · 0 of its ownK173839 Tissue of Origin Test Kit-FFPECancer Genetics, Inc. · 2018
Most influential descendants
Showing 1 of 1 · See all- K173839Tissue of Origin Test Kit-FFPECancer Genetics, Inc. · 2018 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −4 | K941596 | Remedi HS Drug Profiling System | Bio-Rad | 1995 | — |
| −3 | K043341 | Bioplex 2200 Ana Screen with Medical Decision Support Software for Use with… | Bio-Rad Laboratories, Inc. | 2005 | 2 |
| −2 | K080896 | Pathwork Diagnostics Tissue of Origin Test | Pathwork Diagnostics, Inc. | 2008 | — |
| −1 | K092967 | Pathwork Tissue of Origin Test Kit-Ffpe (Origin Test Kit-Ffpe | Pathwork Diagnostics | 2010 | — |
| 0 (this device) | K120489 | Tissue of Origin Test Kit Ffpe | Pathwork Diagnostics, Inc. | 2012 | — |
| +1 | K173839 | Tissue of Origin Test Kit-FFPE | Cancer Genetics, Inc. | 2018 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2018 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in OIW? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K092967 | Pathwork Tissue of Origin Test Kit-Ffpe (Origin Test Kit-FfpeSummary page 1…n Test Kit-FEPE as modified is substantially equivalent to the Pathwork Tissue of Origin Test Kit FFPE cleared under premarket notification k092967 on June 9, 20 10. Pathwork Diagnostics, Inc. CONFIDENTIAL Page 1 ===… | 2010 |
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K173839 | Tissue of Origin Test Kit-FFPE | 2018 | 0 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 17 years and passes through 4 companies; a new generation was cleared every 2.8 years on median.
- 1 of the 4 ancestors has a recall of any class.
- Of its descendants, K173839 (Cancer Genetics, Inc., 2018) has gone furthest, with 0 descendants of its own.
How does its category compare?
All OIW devicesOIW Software, Similarity Score Algorithm, Tissue Of Origin For Malignant Tumor Types: FDA decisions, review times, recalls and adverse event reports over 20 years. 2012, this device’s year, is highlighted.
FDA decisions per year · OIW
1in 2018
2026 to Oct 25, outlined.
Median 510(k) review, days · OIW
Too few OIW 510(k)s in any year since 2007 to give a median.
Recalls per year · OIW
No recall names OIW since 2007.
Adverse event reports per year · OIW
No MAUDE report names OIW since 2007.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 1 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 1 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 1 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 1 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 0 |
| 2022 | 0 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 0 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The Pathwork® Tissue of Origin Test is an invitro diagnostic intended to measure the degree of similarity between the RNA expression patterns in a patient's formalin-fixed, paraffin-embedded (FFPE) tumor and the RNA expression patterns in a database of fifteen tumor types (poorly differentiated, undifferentiated and metastatic cases) that were diagnosed according to then current clinical and pathological practice. This test should be evaluated by a…
Read the full statement (194 words)
The Pathwork® Tissue of Origin Test is an invitro diagnostic intended to measure the degree of similarity between the RNA expression patterns in a patient's formalin-fixed, paraffin-embedded (FFPE) tumor and the RNA expression patterns in a database of fifteen tumor types (poorly differentiated, undifferentiated and metastatic cases) that were diagnosed according to then current clinical and pathological practice. This test should be evaluated by a qualified physician in the context of the patient's clinical history and other diagnostic test results.
Limitations: The Pathwork® Tissue of Origin Test is not intended to establish the origin of tumors (e.g. cancer of unknown primary) that cannot be diagnosed according to current clinical and pathological practice. It is not intended to subclassify or modify the classification of tumors that can be diagnosed by current clinical and pathological practice, nor to predict disease course or survival or treatment efficacy, nor to distinguish primary from metastatic tumor. Tumor types not in the Pathwork Tissue of Origin Test database may have RNA expression patterns that are similar to patterns in the database; therefore, results cannot be used to distinguish tumor types in the database from tumor types not in the database.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K120489 · printed Nov 6, 2026
Cite this page
510(k) Report. “K120489: Tissue of Origin Test Kit Ffpe.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K120489
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026